PA8775501A1 - Conjugado wortmannina-rapalogo y sus usos - Google Patents

Conjugado wortmannina-rapalogo y sus usos

Info

Publication number
PA8775501A1
PA8775501A1 PA20088775501A PA8775501A PA8775501A1 PA 8775501 A1 PA8775501 A1 PA 8775501A1 PA 20088775501 A PA20088775501 A PA 20088775501A PA 8775501 A PA8775501 A PA 8775501A PA 8775501 A1 PA8775501 A1 PA 8775501A1
Authority
PA
Panama
Prior art keywords
wortmannina
conjugate
rapalogo
union
anthineoplastic
Prior art date
Application number
PA20088775501A
Other languages
English (en)
Inventor
Ayral-Kaloustian Semiramis
Gu Jianxin
Ruppen Mark
Zask Arie
Yu Ker
Lucas Judy
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8775501A1 publication Critical patent/PA8775501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

SE DESCRIBE UN CONJUGADO DE WORTMANNINA ANTINEOPLASICO FORMADO POR LA UNION DE UN RAPALOGO CON UNA WORTMANNINA. DICHA UNION SE ELIMINA LUEGO DE LA ADMINISTRACION A UN SUJETO. SE DESCRIBE EL USO DE TAL CONJUGADO EN UN REGIMEN ANTINEOPLASICO.
PA20088775501A 2007-04-05 2008-04-04 Conjugado wortmannina-rapalogo y sus usos PA8775501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92190907P 2007-04-05 2007-04-05

Publications (1)

Publication Number Publication Date
PA8775501A1 true PA8775501A1 (es) 2009-03-31

Family

ID=39639102

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088775501A PA8775501A1 (es) 2007-04-05 2008-04-04 Conjugado wortmannina-rapalogo y sus usos

Country Status (10)

Country Link
US (1) US20080249124A1 (es)
EP (1) EP2134722A1 (es)
JP (1) JP2010523565A (es)
AR (1) AR065930A1 (es)
CA (1) CA2680683A1 (es)
CL (1) CL2008000983A1 (es)
MX (1) MX2009010684A (es)
PA (1) PA8775501A1 (es)
TW (1) TW200845960A (es)
WO (1) WO2008124020A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124026A1 (en) * 2007-04-05 2008-10-16 Wyeth Wortmannin-rapamycin conjugate and uses thereof
US9260484B2 (en) * 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
WO2015179438A1 (en) 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007101A (en) * 1935-02-19 1935-07-02 Arthur L Vonderembse Keyhole illuminator
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
EP0586512A1 (en) * 1991-05-31 1994-03-16 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ATE321053T1 (de) * 1992-10-13 2006-04-15 Wyeth Corp Carbamate von rapamycin
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994025022A1 (en) * 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE69841549D1 (de) * 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2283344T3 (es) * 1999-10-29 2007-11-01 Kosan Biosciences, Inc. Analogos de la rapamicina.
US7081475B2 (en) * 2001-09-14 2006-07-25 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same
PT1589031E (pt) * 2002-07-16 2007-11-28 Biotica Tech Ltd Produção de policétidos e outros produtos naturais
US6745478B2 (en) * 2002-07-18 2004-06-08 Delillo Dominick D. Multi-purpose work knife
CN1809385A (zh) * 2003-04-23 2006-07-26 惠氏控股公司 聚乙二醇化渥曼青霉素轭合物
ES2287772T3 (es) * 2003-08-07 2007-12-16 Wyeth Sintesis regioselectiva de cci-779.
EP1737869A1 (en) * 2004-04-14 2007-01-03 Wyeth a Corporation of the State of Delaware Regiospecific synthesis of rapamycin 42-ester derivatives
CN1942478A (zh) * 2004-04-14 2007-04-04 惠氏公司 用于制备与二羧酸的纳巴霉素42－酯和fk－506 32－酯的方法，用于纳巴霉素配合物的前体和抗体
WO2005100366A1 (en) * 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
EP1740710A1 (en) * 2004-04-27 2007-01-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
PE20060642A1 (es) * 2004-08-10 2006-08-01 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidoximetil)propionico (cci-779) y metodos para su preparacion
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
WO2007086943A2 (en) * 2005-09-01 2007-08-02 Beth Israel Deaconess Medical Center Wortmannin conjugates and uses thereof
CN101394867A (zh) * 2006-03-07 2009-03-25 惠氏公司 大环内酯类免疫抑制剂的水溶性聚乙二醇结合物的制备方法
WO2008124026A1 (en) * 2007-04-05 2008-10-16 Wyeth Wortmannin-rapamycin conjugate and uses thereof

Also Published As

Publication number Publication date
CL2008000983A1 (es) 2008-10-10
EP2134722A1 (en) 2009-12-23
US20080249124A1 (en) 2008-10-09
WO2008124020A1 (en) 2008-10-16
MX2009010684A (es) 2010-01-20
CA2680683A1 (en) 2008-10-16
TW200845960A (en) 2008-12-01
JP2010523565A (ja) 2010-07-15
AR065930A1 (es) 2009-07-08

Similar Documents

Publication Publication Date Title
CR20110553A (es) Terapia complementaria contra el cáncer
AR067347A1 (es) Combinacion antihelmintica
MX2009010683A (es) Conjugado de wortmanina-rapamicina y usos del mismo.
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
ECSP11011459A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
BR112012026801A2 (pt) conjugados de pirrolobenzodiazepina direcionados.
CL2008001446A1 (es) Uso de un probiotico o mezcla de los mismos en la elaboracion de una composicion nutricional o farmaceutica para actuar en el colon en un ambiente pre- o post-quirurgico.
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
GT200800147A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
MX2010005827A (es) Derivados de aminopirazol.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
HN2006009000A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
ECSP088889A (es) Forma nueva de administración de racecadotril
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
CR11838A (es) Compuestos que contienen nitrogeno tricíclico y su uso como antibacterianos
PA8775501A1 (es) Conjugado wortmannina-rapalogo y sus usos
UA108993C2 (en) MEDICINAL COMBINATION WITH THEOBROMINE AND ITS APPLICATION IN Cough
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida
AR075643A4 (es) Mejora introducida en un mini-pilar conico
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos